Polyrizon Rebrands Allergy Candidate as NASARIX, Sets Q3 2026 Trial Start
Early in 2026, Polyrizon rebranded its lead intranasal allergy candidate PL-14 as NASARIX and completed U.S. and EU trademark screenings. It initiated a human factors study on January 22, 2026 under FDA guidance and plans to start Q3 2026 clinical trials for its drug-free Capture and Contain hydrogel spray.
1. Product Branding and Trademark Screening
Polyrizon rebranded its lead intranasal allergy product PL-14 as NASARIX and completed trademark screenings in both the U.S. and European markets early in 2026, establishing clear brand identity ahead of potential commercialization.
2. Innovative Hydrogel Technology
NASARIX leverages the Capture and Contain hydrogel platform to form a thin, bio-adhesive nasal barrier that physically traps allergens such as pollen, dust mites, and pet dander without relying on steroids or antihistamines, demonstrating superior preclinical blocking compared to hydroxypropyl methylcellulose.
3. Clinical Development Milestones
The company initiated a human factors and usability study on January 22, 2026 under FDA guidance to validate instructions and labeling, and is on track to commence formal Q3 2026 clinical trials, positioning NASARIX for a streamlined medical device approval pathway.